Research programme: antibody therapeutics - AnaptysBio

Drug Profile

Research programme: antibody therapeutics - AnaptysBio

Alternative Names: ANA 02; ANA 04; ANA 505; ANB 004; ANB 011; ANB 012; ANB 019; TSR-033

Latest Information Update: 07 Sep 2016

Price : $50

At a glance

  • Originator AnaptysBio
  • Developer AnaptysBio; TESARO
  • Class Antibodies; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action CD223 antigen inhibitors; Checkpoint kinase inhibitors; HAVCR2 protein inhibitors; Immunomodulators; Interleukin 36 receptor antagonists; Interleukin-17 inhibitors; Membrane protein inhibitors; Nerve growth factor inhibitors; PDCD 1 protein inhibitors; Type-II-B activin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pustular psoriasis; Solid tumours
  • Research Cancer; Fibrosis
  • No development reported Autoimmune disorders; Inflammation; Muscular atrophy

Most Recent Events

  • 08 Mar 2017 AnaptysBio plans a phase I trial in Healthy Volunteers and patients with Psoriasis in Australia (ACTRN12617000369325)
  • 08 Mar 2017 AnaptysBio plans phase II trials for Pustular psoriasis and Palmoplantar pustular psoriasis in 2018
  • 08 Mar 2017 TESARO plans a phase I trial for TSR 033 in 2Q 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top